Table 1.
Description of TB cases by HIV status
| HIV uninfected (n = 4013) | HIV infected (n = 10,379) | HIV status not recorded (n = 1817) | Total (n = 16,209) | |
|---|---|---|---|---|
| Sexa | ||||
| Data available | 4013 (100.00) | 10,379 (100.00) | 1817 (100.00) | 16,209 (100.00) |
| Sex female | 1380 (34.39) | 5798 (55.86) | 639 (35.17) | 7817 (48.23) |
| Age | ||||
| Data available | 4012 (99.98) | 10,378 (99.99) | 1817 (100.00) | 16,207 (99.99) |
| Median age (IQR) | 32 (23–46) | 33 (28–40) | 31 (24–43) | 33 (26–41) |
| <25 | 1380 (34.4) | 1587 (15.29) | 578 (31.81) | 3545 (21.87) |
| 25–35 | 907 (22.61) | 4636 (44.67) | 538 (29.61) | 6081 (37.52) |
| 35–45 | 690 (17.2) | 2900 (27.94) | 333 (18.33) | 3923 (24.21) |
| 45–60 | 764 (19.04) | 1164 (11.22) | 278 (15.3) | 2206 (13.61) |
| >60 | 271 (6.75) | 91 (0.88) | 90 (4.95) | 452 (2.79) |
| Anatomic site of TB | ||||
| Data available | 4013 (100.00) | 10,379 (100.00) | 1817 (100.00) | 16,209 (100.00) |
| Pulmonary | 3358 (83.68) | 6805 (65.57) | 1465 (80.63) | 11,628 (71.74) |
| Extra-pulmonary | 543 (13.53) | 2726 (26.26) | 292 (16.07) | 3561 (21.97) |
| Both | 112 (2.79) | 848 (8.17) | 60 (3.30) | 1020 (6.29) |
| Duration of TB treatment | ||||
| Data available | 4013 (100.00) | 10,379 (100.00) | 1817 (100.00) | 16,209 (100.00) |
| Median duration (IQR) | 168 (164–194) | 168 (161–219) | 167 (161–187) | 168 (163–209) |
| Retreatment for TB | ||||
| Data available | 4013 (100.00) | 10,379 (100.00) | 1817 (100.00) | 16,209 (100.00) |
| Retreated case | 1001 (24.94) | 3332 (32.10) | 469 (25.81) | 4802 (29.63) |
| TB smear results | ||||
| Data available | 4013 (100.00) | 10,379 (100.00) | 1817 (100.00) | 16,209 (100.00) |
| Smear negative | 972 (24.22) | 4773 (45.99) | 528 (29.06) | 6273 (38.70) |
| Smear positive | 2716 (67.68) | 4032 (38.85) | 1103 (60.70) | 7851 (48.44) |
| No smear performed | 325 (8.10) | 1574 (15.17) | 186 (10.24) | 2085 (12.86) |
| Outcome | ||||
| Data available | 4013 (100.00) | 10,379 (100.00) | 1817 (100.00) | 16,209 (100.00) |
| Alive | 3237 (80.66) | 7813 (75.28) | 1333 (73.36) | 12,383 (76.40) |
| Dead | 132 (3.29) | 641 (6.18) | 78 (4.29) | 851 (5.25) |
| Lost to follow-up | 405 (10.09) | 1079 (10.40) | 210 (11.56) | 1694 (10.45) |
| Transferred out | 137 (3.41) | 493 (4.75) | 124 (6.82) | 754 (4.65) |
| Not known | 102 (2.54) | 353 (3.40) | 72 (3.96) | 527 (3.25) |
| CD4 count | ||||
| Data available | – | 6433 (61.98) | – | – |
| Median CD4 count (IQR) | – | 146 (65–266) | – | – |
| TMP-SMX during TB treatment | ||||
| Data available | – | 10,012 (96.46) | – | – |
| TMP-SMX during TB treatment | – | 9520 (95.09) | – | – |
| ART during TB treatment | ||||
| Data available | – | 8942 (86.15) | – | – |
| ART during TB treatment | – | 2614 (29.23) | – | – |
Data shows number of cases (n) and percentage (%) unless otherwise specified
IQR inter-quartile range, TB active tuberculosis, TMP-SMX trimethoprim sulfamethoxazole 160/80 mg chemoprophylaxis
aA total of 15,556 patients experienced 16,209 cases of tuberculosis. The female proportions for these 15,556 patients are: 48.6 % (7552/15,556) of all patients; 34.7 % (1347/3886) of HIV uninfected patients; 56.3 % (5584/9923) of HIV infected patients; and 35.6 % (621/1747) of patients with HIV status not recorded